Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up – Should You Buy?

Telix Pharmaceuticals Limited (NASDAQ:TLX) gapped up before the market opened on Wednesday . The stock had previously closed at $10.21, but opened at $10.81. Telix Pharmaceuticals shares last traded at $10.9050, with a volume of 56,813 shares.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on TLX. Wall Street Zen raised shares of Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, April 11th. Citigroup raised their target price on shares of Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a “buy” rating in a research note on Tuesday, February 24th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a report on Monday, April 13th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Monday, April 20th. Finally, Wedbush reiterated an “outperform” rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a research note on Monday, April 13th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Telix Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $21.12.

Telix Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. The firm’s 50-day simple moving average is $10.12 and its 200 day simple moving average is $8.73.

Insider Activity at Telix Pharmaceuticals

In related news, CEO Christian Behrenbruch acquired 33,435 shares of the firm’s stock in a transaction that occurred on Wednesday, April 29th. The shares were purchased at an average price of $14.87 per share, with a total value of $497,178.45. Following the completion of the acquisition, the chief executive officer owned 20,742,935 shares in the company, valued at approximately $308,447,443.45. This represents a 0.16% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in TLX. Rhumbline Advisers lifted its position in shares of Telix Pharmaceuticals by 117.3% during the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after acquiring an additional 1,392 shares during the period. XTX Topco Ltd purchased a new stake in shares of Telix Pharmaceuticals during the 4th quarter worth approximately $89,000. Bank of America Corp DE grew its holdings in shares of Telix Pharmaceuticals by 523.8% in the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after acquiring an additional 8,423 shares during the period. OLD Mission Capital LLC acquired a new stake in shares of Telix Pharmaceuticals in the 4th quarter worth approximately $111,000. Finally, XY Capital Ltd purchased a new position in Telix Pharmaceuticals in the 1st quarter valued at approximately $120,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.